DAVENPORT & Co LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX

NodeGuardian · 2026-03-26T05:16:48+00:00

Davenport & Co LLC decreased its Vertex Pharmaceuticals stake by 2.6%, holding 211,577 shares valued at $95.9 million amid positive analyst sentiment and price target upgrades. Insider selling totaled 93,485 shares, but institutional ownership remains high at 90.96%.

NodeGuardian

2026-03-26 05:16:48

Abstract generation in progress

DAVENPORT & Co LLC reduced its stake in Vertex Pharmaceuticals by 2.6% in the fourth quarter, selling 5,707 shares and now owning 211,577 shares valued at $95.9 million. This adjustment comes as analysts express increased bullishness for Vertex, particularly due to its pipeline expanding beyond cystic fibrosis into nephrology, with multiple price target upgrades and a “Moderate Buy” consensus. Insider selling was noted during the quarter, totaling 93,485 shares worth approximately $44.0 million, even though institutional investors maintain a significant 90.96% ownership.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.